| Astral Resources NL (AAR) ORDINARY FULLY PAID |
Materials |
$464 |
Feysville - Grant of Mining Lease M26-846
|
12 Jan 2026 8:50AM |
$0.265 |
$0.258 |
fallen by
2.83%
|
|
| Environmental Clean Technologies Limited (ECT) ORDINARY FULLY PAID |
Industrials |
$49 |
Appointment of Hirokazu Minami to Advisory Board
|
12 Jan 2026 8:49AM |
$0.165 |
$0.118 |
fallen by
28.79%
|
|
| PM Capital Global Opportunities Fund Limited (PGF) ORDINARY FULLY PAID |
Financials |
$1,497 |
Net Tangible Asset Backing - 9 January 2026
|
12 Jan 2026 8:48AM |
$2.980 |
$3.120 |
risen by
4.70%
|
|
| Bluglass Limited (BLG) ORDINARY FULLY PAID |
Information Technology |
$24 |
BLG secures A$1.05M CLAWS Hub contract extension with US DoW
|
12 Jan 2026 8:46AM |
$0.240 |
$0.185 |
fallen by
22.92%
|
|
BLG - Price-sensitive ASX Announcement
Full Release
Key Points
- BluGlass and North Carolina State University extended their contract for a third year under the U.S. DoW’s Microelectronics Commons Program.
- The contract extension is valued at A$1.05 million, bringing the total contract value to A$6.5 million over three years.
- BluGlass focuses on developing GaN lasers for defence, quantum, and dual-use applications.
- The CLAWS Hub is part of a broader initiative by the U.S. Department of War to develop next-generation microelectronics.
- BluGlass achieved significant improvements in power conversion efficiency and DFB laser capabilities.
- The contract supports BluGlass' role in advancing critical quantum and defence technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$80 |
Notification of cessation of securities - M7T
|
12 Jan 2026 8:43AM |
$0.615 |
$0.340 |
fallen by
44.72%
|
|
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$101 |
Notification of cessation of securities - CAM
|
12 Jan 2026 8:42AM |
$0.700 |
$0.700 |
fallen by
0%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$562 |
CLINUVEL - injectable peptide platform in preclinical study
|
12 Jan 2026 8:42AM |
$12.640 |
$11.190 |
fallen by
11.47%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Clinuvel starts preclinical study for injectable peptide platform VLRX-L.
- VLRX-L is designed for controlled-release of peptides including melanocortins.
- Preclinical study focuses on safety, kinetics, and reproducibility of drug release.
- VLRX-L is the first platform from Clinuvel's Singapore RD&I Centre.
- Completion of the preclinical program is expected by H2 2026.
- Expansion of VALLAURIX RD&I Centre to support injectable formulations.
- Investment plan supported by Singaporean Economic Development Board.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Super Retail Group Limited (SUL) ORDINARY FULLY PAID |
Consumer Discretionary |
$3,156 |
Trading Update
|
12 Jan 2026 8:41AM |
$15.720 |
$13.975 |
fallen by
11.10%
|
|
SUL - Price-sensitive ASX Announcement
Full Release
Key Points
- Super Retail Group (ASX:SUL) reported its trading performance for the first half of FY26.
- Group's first half revenue expected to be $2.2 billion.
- First half normalised profit before tax expected between $172 million and $175 million.
- Supercheap Auto showed a revenue growth of 5.1% with a solid performance.
- rebel achieved like-for-like sales growth of 3.8% with lower gross margins due to higher promotions.
- BCF saw a decline in sales, impacted by weather conditions in Victoria and South Australia.
- Macpac realized strong sales momentum with a 13.1% increase.
- The Group maintained positive cash balance with no bank debt at the end of the first half.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$101 |
Update - Notification of buy-back - CAM
|
12 Jan 2026 8:39AM |
$0.700 |
$0.700 |
fallen by
0%
|
|
| RocketDNA Ltd (RKT) ORDINARY FULLY PAID |
Information Technology |
$28 |
Vesting of 2025 Performance Rights
|
12 Jan 2026 8:39AM |
$0.030 |
$0.024 |
fallen by
20%
|
|
| Larvotto Resources Limited (LRV) ORDINARY FULLY PAID |
Materials |
$715 |
Drilling at Metz Continues to Deliver
|
12 Jan 2026 8:35AM |
$1.190 |
$1.380 |
risen by
15.97%
|
|
LRV - Price-sensitive ASX Announcement
Full Release
Key Points
- Drilling at the Blacklode Prospect reveals significant antimony and gold mineralisation.
- Near surface high-grade mineralisation extends the western extension of the Metz system.
- Key intercepts include BLK106: 6m @ 8.50g/t AuEq from 92m and BLK107: 16m @ 5.43g/t AuEq from 294m.
- Significant tungsten mineralisation associated with antimony-gold lodes intersected.
- The Metz system shows extensive exploration potential despite its long history.
- Larvotto Resources aims to expand resource base and identify new mineralised splays.
- The exploration programs are part of a strategy to deliver additional mineable material to the Metz Mining Centre.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$1,189 |
2025 NPAT guidance of $145m, performance fee upgrade
|
12 Jan 2026 8:35AM |
$3.400 |
$3.220 |
fallen by
5.29%
|
|
RPL - Price-sensitive ASX Announcement
Full Release
Key Points
- 2025 NPAT guidance of $145 million driven by performance fee upgrade.
- Funds under management rose to $20.8 billion as of December 2025.
- Net inflows for the December quarter were approximately $80 million.
- Total net inflows for 2025 reached $1.5 billion.
- Preliminary unaudited estimates subject to finalization and review.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$417 |
Update - Notification of buy-back - RG8
|
12 Jan 2026 8:33AM |
$2.750 |
$2.860 |
risen by
4%
|
|
| Litchfield Minerals Limited (LMS) ORDINARY FULLY PAID |
Materials |
$36 |
EM Defines 3000-Siemens Conductor & 1km Carbonate Unit - VT1
|
12 Jan 2026 8:33AM |
$0.480 |
$0.620 |
risen by
29.17%
|
|
LMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Ground EM at VT1 defined six conductor plates with high conductance.
- A 1km carbonate unit was identified, indicating a potential new mineral zone.
- VT2 surveys validated existing data and discovered new chargeability anomalies.
- Exploration in 2026 will focus on deepening investigations with advanced geophysical techniques.
- Targeted drilling will aim to expand the near-surface resource base and explore deeper targets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Firebrick Pharma Limited (FRE) ORDINARY FULLY PAID |
Health Care |
$13 |
Update on Registration of Nasodine in the Philippines
|
12 Jan 2026 8:32AM |
$0.066 |
$0.053 |
fallen by
19.70%
|
|
| EBR Systems Inc (EBR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$329 |
EBR to Present at 44th Annual JP Morgan Health Conference
|
12 Jan 2026 8:32AM |
$0.985 |
$0.730 |
fallen by
25.89%
|
|
| Stockland (SGP) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$12,185 |
Notification of cessation of securities - SGP
|
12 Jan 2026 8:31AM |
$5.530 |
$5.030 |
fallen by
9.04%
|
|
| EBR Systems Inc (EBR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$329 |
Strong Q4 FY2025 Commercial and Clinical Progress
|
12 Jan 2026 8:30AM |
$0.985 |
$0.730 |
fallen by
25.89%
|
|
EBR - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong commercial momentum in Q4 2025.
- Doubling of case volumes with WiSE System implants.
- Expected revenue range for Q4 2025 is US$870K to US$935K.
- Total revenue for 2025 projected to be US$1,552K to US$1,617K.
- Commencement of the WiSE-UP post-approval study.
- Initiation of the TLC-AU feasibility study.
- 9 additional purchase agreements signed.
- 11 new physicians trained for WiSE System implantation.
- Active investor engagement and participation in conferences.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Stockland (SGP) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$12,185 |
Notification regarding unquoted securities - SGP
|
12 Jan 2026 8:30AM |
$5.530 |
$5.030 |
fallen by
9.04%
|
|
| Regal Partners Global Investments Limited (RG1) ORDINARY FULLY PAID |
Financials |
$546 |
Update - Notification of buy-back - RG1
|
12 Jan 2026 8:29AM |
$2.310 |
$2.260 |
fallen by
2.16%
|
|
| Cyclopharm Limited (CYC) ORDINARY FULLY PAID |
Health Care |
$106 |
Stanford Children's Health to Implement Technegas
|
12 Jan 2026 8:28AM |
$0.940 |
$0.875 |
fallen by
6.91%
|
|
CYC - Price-sensitive ASX Announcement
Full Release
Key Points
- Cyclopharm Limited partners with Stanford Medicine Children’s Health.
- Lucile Packard Children’s Hospital Stanford to implement Technegas.
- First U.S. children's hospital to adopt Technegas.
- Technegas offers low radiation dose, ideal for pediatric use.
- Cyclopharm expanding U.S. installations for broader access.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$4,657 |
Notice of FY26 Half Year Results Announcement
|
12 Jan 2026 8:28AM |
$33.490 |
$32.380 |
fallen by
3.31%
|
|
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$612 |
Weekly NTA 09.01.2026
|
12 Jan 2026 8:28AM |
$3.260 |
$2.750 |
fallen by
15.64%
|
|
| RAM Essential Services Property Fund (REP) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$271 |
Dividend Details
|
12 Jan 2026 8:28AM |
$0.573 |
$0.540 |
fallen by
5.68%
|
|
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$635 |
FDA Clears VISION-MR Diagnostic Catheter
|
12 Jan 2026 8:28AM |
$1.580 |
$1.980 |
risen by
25.32%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA grants 510(k) clearance for Vision-MR Diagnostic Catheter.
- First FDA clearance for Imricor Medical Systems Inc.
- Catheter designed for use with real-time MRI guidance.
- Part of Imricor’s MRI-compatible electrophysiology device platform.
- Clearance allows marketing in the US, the largest electrophysiology market.
- Steve Wedan highlights milestone and team effort.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.